Triple
T22690402
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Loxo Oncology |
E561034
|
entity |
| Predicate | notableDrugCandidate |
P7501
|
FINISHED |
| Object | larotrectinib |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: larotrectinib | Statement: [Loxo Oncology, notableDrugCandidate, larotrectinib]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: larotrectinib Context triple: [Loxo Oncology, notableDrugCandidate, larotrectinib]
-
A.
larotrectinib
chosen
Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
-
B.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
-
C.
neratinib
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
-
D.
fam-trastuzumab deruxtecan
Fam-trastuzumab deruxtecan is an antibody–drug conjugate used primarily to treat HER2-positive cancers by delivering a cytotoxic payload directly to HER2-expressing tumor cells.
-
E.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: notableDrugCandidate Context triple: [Loxo Oncology, notableDrugCandidate, larotrectinib]
-
A.
hasNotableDrug
chosen
Indicates that an entity is associated with a drug that is considered notable or significant in some recognized context.
-
B.
developedDrugFor
Indicates that one entity created or formulated a drug intended to treat or address a medical condition associated with another entity.
-
C.
potentialTherapeuticUse
Indicates that something is being considered or investigated as a possible treatment or therapy for a condition or disease.
-
D.
hasMolecularTarget
Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).
-
E.
notableBiosimilarArea
Indicates that an entity is significantly involved in, or recognized for, work related to a particular biosimilar product or therapeutic area.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454d71b48190a1f80af9f82b6fcf |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1789a1fd08190bce5fa0babe695d3 |
completed | April 29, 2026, 3:18 a.m. |
| PD | Predicate disambiguation | batch_69ee62b2259c819091ed1387a748b9f3 |
completed | April 26, 2026, 7:08 p.m. |
Created at: April 17, 2026, 3:13 p.m.